• Quantitative Western ligand blotting reveals common patterns and differential features of IGFBP-fingerprints in domestic ruminant breeds and species.
    Wirthgen E, Höflich C, Spitschak M, Helmer C, Brand B, Langbein J, Metzger F, Hoeflich A.
    Growth Horm IGF Res. 2015 Nov 10. pii: S1096-6374(15)30033-2
  • Methylating micronutrient supplementation during pregnancy influences foetal hepatic gene expression and IGF signalling and increases foetal weight.
    Oster M, Nuchchanart W, Trakooljul N, Muráni E, Zeyner A, Wirthgen E, Hoeflich A, Ponsuksili S, Wimmers K.
    Eur J Nutr. 2015 Jul 14
  • Validation of serum IGF-I as a biomarker to monitor exogenous growth hormone agonist and antagonist bioactivity in rabbits.
    Bielohuby M, Zarkesh-Esfahani SH, Manolopoulou J, Wirthgen E, Walpurgis K, Toghiany Khorasgani M, Aghili ZS, Wilkinson IR, Hoeflich A, Thevis M, Ross RJ, Bidlingmaier
    M. Dis. Model. Mech. 2014 Sep 19. pii: dmm.016519
  • Polyethylene glycol-coupled IGF1 delays motor function defects in a mouse model of spinal muscular atrophy with respiratory distress type 1.
    Krieger F, Elflein N, Saenger S, Wirthgen E, Rak K, Frantz S, Hoeflich A, Toyka KV, Metzger F, Jablonka S.
    Brain. 2014 May;137(Pt 5):1374-93
  • Effects of parturition and feed restriction on concentrations and distribution of the insulin-like growth factor binding proteins in plasma and cerebrospinal fluid of dairy cows.
    Laeger T and Wirthgen E, Piechotta M, Metzger F, Metges CC, Kuhla B, Hoeflich A
    J Dairy Sci. 2014 May;97(5):2876-85
  • Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus.
    Huguet A, Medja F, Nicole A, Vignaud A, Guiraud-Dogan C, Ferry A, Decostre V, Hogrel JY, Metzger F, Hoeflich A, Baraibar M, Gomes-Pereira M, Puymirat J, Bassez G, Furling D, Munnich A, Gourdon G.
    PLoS Genet. 2012 Nov;8(11):e1003043. doi: 10.1371/journal.pgen.1003043. Epub 2012 Nov 29.
  • Serum IGF-I is not a reliable pharmacodynamic marker of exogenous growth hormone activity in mice.
    Bielohuby M, Schaab M, Kummann M, Sawitzky M, Gebhardt R, Binder G, Frystyk J, Bjerre M, Hoeflich A, Kratzsch J, Bidlingmaier M.
    Endocrinology. 2011 Dec;152(12):4764-76.
  • Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I.
    Metzger F, Sajid W, Saenger S, Staudenmaier C, van der Poel C, Sobottka B, Schuler A, Sawitzky M, Poirier R, Tuerck D, Schick E, Schaubmar A, Hesse F, Amrein K, Loetscher H, Lynch GS, Hoeflich A, De Meyts P, Schoenfeld HJ.
    J Biol Chem. 2011 Jun 3;286(22):19501-10.
  • IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis.
    Diehl D, Hessel E, Oesterle D, Renner-Müller I, Elmlinger M, Langhammer M, Göttlicher M, Wolf E, Lahm H, Hoeflich A.
    Int J Cancer. 2009 May 1;124(9):2220-5.
  • Contrasting bone effects of temporary versus permanent IGFBP administration in rodents.
    Hoeflich A.
    Growth Horm IGF Res. 2008 Jun;18(3):181-7. doi: 10.1016/j.ghir.2008.01.003. Epub 2008 Mar 4.
  • Insulin-like growth factor (IGF)-binding protein-4 inhibits colony formation of colorectal cancer cells by IGF-independent mechanisms.
    Diehl D, Hoeflich A, Wolf E, Lahm H.
    Cancer Res. 2004 Mar 1;64(5):1600-3.
  • Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?
    Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Wolf E.
    Cancer Res. 2001 Dec 15;61(24):8601-10. Review.
  • Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2.
    Hoeflich A, Nedbal S, Blum WF, Erhard M, Lahm H, Brem G, Kolb HJ, Wanke R, Wolf E.
    Endocrinology. 2001 May;142(5):1889-98.
  • Genome-wide search for loci controlling serum IGF binding protein levels of mice.
    Brockmann GA, Haley CS, Wolf E, Karle S, Kratzsch J, Renne U, Schwerin M, Hoeflich A.
    FASEB J. 2001 Apr;15(6):978-87.
  • Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells.
    Hoeflich A, Fettscher O, Lahm H, Blum WF, Kolb HJ, Engelhardt D, Wolf E, Weber MM.
    Cancer Res. 2000 Feb 15;60(4):834-8.
  • Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain.
    Hoeflich A, Wu M, Mohan S, Föll J, Wanke R, Froehlich T, Arnold GJ, Lahm H, Kolb HJ, Wolf E.
    Endocrinology. 1999 Dec;140(12):5488-96.
  • Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: correlation with metabolic control and height attainment.
    Strasser-Vogel B, Blum WF, Past R, Kessler U, Hoeflich A, Meiler B, Kiess W.
    J Clin Endocrinol Metab. 1995 Apr;80(4):1207-13.
  • Human IM-9 lymphoblasts as a model of the growth hormone-insulin-like growth factor axis: gene expression, and interactions of ligands with receptors and binding proteins.
    Yang Y, Hoeflich A, Kessler U, Barenton B, Blum W, Schwarz HP, Kiess W.
    Regul Pept. 1993 Oct 20;48(1-2):41-53.